258 related articles for article (PubMed ID: 15927827)
21. Latent class joint model of ovarian function suppression and DFS for premenopausal breast cancer patients.
Zhang JJ; Wang M
Stat Med; 2010 Sep; 29(22):2310-24. PubMed ID: 20552577
[TBL] [Abstract][Full Text] [Related]
22. Ovarian ablation as a treatment for breast cancer.
Sainsbury R
Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
[TBL] [Abstract][Full Text] [Related]
23. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
25. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
26. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
28. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
29. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
[TBL] [Abstract][Full Text] [Related]
30. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.
Morgan DA; Refalo NA; Cheung KL
Breast; 2011 Jun; 20(3):215-9. PubMed ID: 21159509
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant therapy for premenopausal patients with early breast cancer.
Kurebayashi J
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
[TBL] [Abstract][Full Text] [Related]
33. [Hormonal treatment in breast cancer].
Delozier T
J Gynecol Obstet Biol Reprod (Paris); 2010 Dec; 39(8 Suppl):F71-8. PubMed ID: 21074336
[TBL] [Abstract][Full Text] [Related]
34. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
35. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
36. [Adjuvant endocrine therapy in breast cancer].
Huober J; Thürlimann B
Ther Umsch; 2008 Apr; 65(4):193-200. PubMed ID: 18622910
[TBL] [Abstract][Full Text] [Related]
37. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
38. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
39. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
[TBL] [Abstract][Full Text] [Related]
40. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
Nomura Y; Tsutsui S; Murakami S; Takenaka Y
Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]